Condition (MeSH)
Vulvar Lichen Sclerosus
ClinicalTrials.gov lists 33 trials for Vulvar Lichen Sclerosus or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
33 of the 33 trials are tagged with Vulvar Lichen Sclerosus itself; the rest are tagged with a narrower condition beneath it.
When did Vulvar Lichen Sclerosus trials start? (15)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 2 |
| 2024 | 2 |
| 2023 | 3 |
| 2022 | 5 |
| 2021 | 4 |
| 2020 | 1 |
| 2019 | 1 |
| 2018 | 3 |
| 2017 | 1 |
Showing 10 of 15 earlier years.
No forecast is made for this condition: it averages 3.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Vulvar Lichen Sclerosus trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 2 |
| Phase 2 | 6 |
| Phase 2/3 | 2 |
| Phase 3 | 2 |
| Phase 4 | 1 |
| Not applicable | 17 |
| Observational | 2 |
How many Vulvar Lichen Sclerosus trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 4 |
| Recruiting | 5 |
| Completed | 18 |
| Terminated | 3 |
| Withdrawn | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Vulvar Lichen Sclerosus trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| 1st Federal Budgetary Healthcare Institution Volga District Medical Center | 1 |
| Candela Corporation | 1 |
| Dermtreat | 1 |
| Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare | 1 |
Which drugs are being tested for Vulvar Lichen Sclerosus? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Clobetasol | 2 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Clobetasol 0.05% ointment | 3 |
| [PRP] platelet rich plasma | 2 |
| StrataMGT | 2 |
| Low Level Laser Therapy | 1 |
| Clobetasol cream | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Vulvar Lichen Sclerosus? (50)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| A randomized controlled trial to evaluate a novel dual laser therapy for vulvar lichen sclerosus: exploratory study assessing the impact of menopausal status. | Menopause (New York, N.Y.) | 2025 | Yes |
| Treatment of Refractory Vulvar Lichen Sclerosus With Methotrexate. | Journal of lower genital tract disease | 2024 | Yes |
| Vulvar Lichen Sclerosus: What's New? | Cutis | 2024 | Yes |
| Nd:YAG/Er:YAG dual laser vs. topical steroid to treat vulvar lichen sclerosus: study protocol of a randomized controlled trial. | Archives of gynecology and obstetrics | 2023 | Yes |
| LASER treatment in gynaecology -A randomized controlled trial in women with symptomatic lichen sclerosus. | European journal of obstetrics, gynecology, and reproductive biology | 2023 | Yes |
Showing 5 of 50 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.